CPX-351 therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukaemia (AML) between 60 and 75 years of age.
The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP), promising first-line treatment for patients with ITP.
The dual therapy demonstrated durable and deep responses in heavily pre-treated patients with refractory MM. The combination regimen was tolerable and did not show overlapping toxicity. It is therefore a promising option for treating patients with MM.
Combination therapy of eprenetapopt plus azacytidine showed efficacy and safety in patients with TP53-mutant myelodysplastic syndrome and oligoblastic acute myeloid leukaemia.
Immune-mediated inflammatory disease treated with a TNFα inhibitor had a 2-fold increased risk of new-onset psoriasis compared with conventional therapy.
Pooled safety analyses of 2 phase 3 trials revealed similar tolerability of the IL-17A inhibitor secukinumab in children and adolescents with moderate-to-severe plaque psoriasis.
Digital health apps offer those affected by depression the possibility of supporting psychotherapy. Dr. sc. hm. Gwendolyn Mayer explains what these apps are about, who they are suitable for and how effective they are.
When a person is at the end of their life, it means change. At Heidelberg University Hospital, a team of therapists works with the concept of Dignity Therapy according to Chochinov and expands it to include the aspect of couple relationships.
The number of mental illnesses worldwide is growing - and with it the need for good therapies. What is the benefit of treating depression and anxiety with virtual reality? Researchers from New Zealand have evaluated studies.
What does the Covid-19 pandemic do to people psychologically? This questions was addressed in a lecture at the University Hospital Jena, Germany.
Most rheumatism drugs can be used safely in SARS-CoV-2 infections. Some even seem to protect against severe cases, but individual drugs were associated with a complicated disease path.
Recent advances in immuno-oncology could open up new treatment options for cardiovascular diseases in the future. A team from Heidelberg (Germany) and Stanford (USA) has found decisive steps in this direction.
Dr. Bianco shares his thoughts on the condition of hospitalised patients, in particular the elderly, and stresses the importance of humanising care in the medical profession.
An international team succeeds on the path to better understand the manifestations of this hereditary disease.
The Roman legions are considered a model of military efficiency. Military medicine was structured, including Greek influences and rituals, to provide care to these exceptional combatants.
An annotated guide to the Guidelines for Home Treatment of SARS-CoV-2 infections - by Dr Carla Bruschelli
Progression of disability in patients with POMS can be predicted by relapse frequency, greater number of relapses with incomplete recovery, amongst others.
PPMS who were originally randomised to ocrelizumab had a lower risk of disability progression than original placebo receivers after 8-years of follow-up.
Ibudilast was associated with reduced retinal atrophy compared with placebo in patients with primary progressive MS (PPMS). This was not the case for SPMS.
Ublituximab was superior to teriflunomide in relapsing MS patients. Annualised relapse rates and MRI parameters demonstrated this.